{"name":"Nihon Pharmaceutical Co., Ltd","slug":"nihon-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"nihon-pharm.co.jp","description":"","hq":"Tokyo","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"NPB-01","genericName":"NPB-01","slug":"npb-01","indication":"Other","status":"phase_3"},{"name":"NPB-01-ME","genericName":"NPB-01-ME","slug":"npb-01-me","indication":"Other","status":"phase_3"},{"name":"Suprep Bowel Prep Kit","genericName":"POTASSIUM SULFATE","slug":"potassium-sulfate","indication":"Bowel and colon cleansing preparation for colonoscopy","status":"marketed"},{"name":"Moviprep（1-day treatment）","genericName":"Moviprep（1-day treatment）","slug":"moviprep-1-day-treatment","indication":"Bowel cleansing prior to colonoscopy","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"NPO-11","genericName":"NPO-11","slug":"npo-11","indication":"Type 2 diabetes","status":"phase_3"},{"name":"NPB-06","genericName":"NPB-06","slug":"npb-06","indication":"Type 2 diabetes","status":"phase_3"},{"name":"NPF-08 （1-day treatment）","genericName":"NPF-08 （1-day treatment）","slug":"npf-08-1-day-treatment","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"NPF-08 （2-day split dose）","genericName":"NPF-08 （2-day split dose）","slug":"npf-08-2-day-split-dose","indication":"Hypertension","status":"phase_3"}]}],"pipeline":[{"name":"NPB-01","genericName":"NPB-01","slug":"npb-01","phase":"phase_3","mechanism":"NPB-01 is a novel therapeutic agent in phase 3 development by Nihon Pharmaceutical Co., Ltd.","indications":[],"catalyst":""},{"name":"NPB-01-ME","genericName":"NPB-01-ME","slug":"npb-01-me","phase":"phase_3","mechanism":"NPB-01-ME is a methyl ester prodrug formulation designed to improve the bioavailability and pharmacokinetic properties of its active parent compound.","indications":[],"catalyst":""},{"name":"NPO-11","genericName":"NPO-11","slug":"npo-11","phase":"phase_3","mechanism":"NPO-11 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Suprep Bowel Prep Kit","genericName":"POTASSIUM SULFATE","slug":"potassium-sulfate","phase":"marketed","mechanism":"Small molecule","indications":["Bowel and colon cleansing preparation for colonoscopy"],"catalyst":""},{"name":"Moviprep（1-day treatment）","genericName":"Moviprep（1-day treatment）","slug":"moviprep-1-day-treatment","phase":"phase_3","mechanism":"Moviprep is an osmotic laxative bowel preparation that draws water into the colon to cleanse it before medical procedures.","indications":["Bowel cleansing prior to colonoscopy","Bowel cleansing prior to other gastrointestinal procedures"],"catalyst":""},{"name":"NPB-06","genericName":"NPB-06","slug":"npb-06","phase":"phase_3","mechanism":"NPB-06 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"NPF-08 （1-day treatment）","genericName":"NPF-08 （1-day treatment）","slug":"npf-08-1-day-treatment","phase":"phase_3","mechanism":"NPF-08 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"NPF-08 （2-day split dose）","genericName":"NPF-08 （2-day split dose）","slug":"npf-08-2-day-split-dose","phase":"phase_3","mechanism":"NPF-08 is a small molecule that targets the renin-angiotensin system to lower blood pressure.","indications":["Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPZlBsVWs1ckU2TmZpX1dIOVVkQ1pzcDJZZTJ6VHc5VDlLYi04MGNFazRGSGNkdy1NSmFQUVVTckFsTzBLSGtfdlROb013QnhtcU44cXpBdy1aUTh6WUQwTEJZbjlqbHozWjZYdUZoUHJPQnh1YW1OV0dydXJpaWgwcXU3Z1ZIYWp5NzEzb3NXcGhEcml5ZHo2Z1F5V1VhV1BNejNiVnhZdUdldUxzLU9raWZLS3Z1dHBTM2ZSVmhjcWlLUkJPNDRsSV9yQmtXR3l1WWxmSU9FZE95R1l3S29nVVRwbjFwRTNuWVdWQVhZam5zWWxsdmlqRUpselhtM01tR3lOaA?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Bullous Pemphigoid Market Forecast 2034: Explore Next-Gen Treatments, Regulatory Milestones, and Competitive Intelligence | DelveInsight - Barchart.com","headline":"Bullous Pemphigoid Market Forecast 2034: Explore Next-Gen Treatments, Regulatory Milestones, and Competitive Intelligenc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFByZGhHdnRKdWp0OWl2MjNZOHhtVF85XzRJOFpoRUpnYnBXRDhKRk5qREZCam1QeEJmLXNjUzd6SmpXNl9pd294NHVVMFhjR2RfU2dvTVJVbU9DVjJhOGFMc3ByNnBoSm84S2RSX3BJOGtjNWlxMTRTU2Zn?oc=5","date":"2025-12-20","type":"trial","source":"Wiley","summary":"Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials - Wiley","headline":"Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer tri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNS2FEdHhoYW9EWEQzQ1ZrbU1jSVNPeW9vVVMwaXQ0UDRWcS1NRjd2QXZRQXFJb2MtSlU3eDNiMGNSTnprdi1QOWpxU1M4cXNzMXJIZEhjaW4yRnlGTnVsc2NRVGRKNEFWdVJ1S0lmN0JwdWlBUDh3aDFvakp6NlFvbTN5dEVRSTZwTV85a3YzSDJ5QQ?oc=5","date":"2025-08-17","type":"pipeline","source":"Frontiers","summary":"B cell depletion as a therapeutic strategy for neuromyelitis optica spectrum disorder: rationale, evidence, and challenges - Frontiers","headline":"B cell depletion as a therapeutic strategy for neuromyelitis optica spectrum disorder: rationale, evidence, and challeng","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1BZHRmMmdpQWplZlV5M2JYbTlXYW90b3NHOS1JRzc1YXFTV1pvOFlBNTRKY1dIU01IYUdOZW9JV1VqdTk1MmNyZElMSTRIUUhHNUdzdjFjbEFUNl8wYlB1X1RpanFFblc0RlE?oc=5","date":"2025-07-23","type":"pipeline","source":"Wiley Online Library","summary":"Co-Occurrence of High-Frequency Oscillations and Interictal Focal Paroxysmal Fast Activity During Scalp EEG: A Comparison With Single Spikes - Wiley Online Library","headline":"Co-Occurrence of High-Frequency Oscillations and Interictal Focal Paroxysmal Fast Activity During Scalp EEG: A Compariso","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOSldmV1dEVEU5Z2Y0alo1bUZqby12SURWRTNON0NMRFhMRkdFY25KdDRaRDhHUkNvQmZ6NTBlOGlYaXRoeWVlZVZvblctVVZ4ZUE0NEFTejZzeDc3NnF2dEpHOHp5ek85cU1RVlViOVlGbnB6ZTVnVXNaTWdPSXQ4aU1GUWZQRlVoQjBmMkpBdFBGeUFvdG14U0ZhMFZGQnVReThmSml3TQ?oc=5","date":"2025-04-02","type":"deal","source":"BioWorld News","summary":"GE Healthcare taps into Japan radiopharma market with Nihon buy - BioWorld News","headline":"GE Healthcare taps into Japan radiopharma market with Nihon buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNc3E5SE51Z1pnbnpsQU4tMFpKbXJpM2NnWGYxSWRzdkpVNlJQdmtXNmtuc2dueHNCcHdLcmtSLU5PbWxReDFUak1Va0ZlbnVLWmItODdtRDhkSy1iR3hTcFNjZW5VYlBFZ24yYWE0U3NxNWsyWlJFc1RZQlVVUEpKWlY1SFZmXy1OcXRqSFhXR3FKdzBQaWFFamhCcFBTZWx2RkdkVFZoX055Z01CYndkVzh6NGp5R3hIV3l3MmlGUlNZLVBFS3dkTjlYbUVQZzk2V0cybFgtcUVnaDNwaUlwQjQ3aWljbktYLXp6QlItOGNXU0dJVTNrbQ?oc=5","date":"2025-03-31","type":"pipeline","source":"businesswire.com","summary":"GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan - businesswire.com","headline":"GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxObk1yWFpRRjBnMTY2aFN6Y0VNSFR1VHZFOERrUkJmbjdUU2FFZHRwX0FjMGVGVUNvc2JIeHVmRTcyZUNGaDFHRkdMSmtwWFRkaGU2MmdGaWE4cG5GZldzTFBPYTZ1VjViR2ZTZWhlcTJfM3FRR3ByV0JoRUdsM1JNcFhvVmJKN0RvZ0luSjQ3Q0ROMWhEN2c?oc=5","date":"2024-12-05","type":"regulatory","source":"Imaging Technology News","summary":"GE HealthCare Acquires Remaining Stake in Nihon Medi-Physics - Imaging Technology News","headline":"GE HealthCare Acquires Remaining Stake in Nihon Medi-Physics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNOHBfY19RZ25mUzRWdm0zTEtNQ2lldzRRZzh6Rkx5dEtPTTV2R2JlWXRHRll2NnRwRGtNZkdmLXdLaFZ6X2ZTZlZ5ZnY2RVF4ZXg2SC1YVXRGc0FoWkhzdTl0TWtueEdMaTRtVGY5Y2tSYy1QVFVUTjNoUm8yaDl5cUYtcjhibHNvOVlwT1dWUnBvakFvUERFcmR4NXlSeU9iRnViYlJrZVplM3RBeVhRR2p0OVRlc21Cb3I3RnZsNno2aGk5aHZVLXE3NlV3Nk1pUVlEdDRQOXpFUW9r?oc=5","date":"2024-05-29","type":"pipeline","source":"cureus.com","summary":"Unveiling, Analyzing the Mechanisms of, and Proposing Solutions for Bribery in Japan's Medical Device Sector - cureus.com","headline":"Unveiling, Analyzing the Mechanisms of, and Proposing Solutions for Bribery in Japan's Medical Device Sector","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9nYnh5VnFkZ0hubm9TeUw0ck5JRGZBZm1WcnF1Y3VBUTlGc3NJek9NTmNrYVNsN2MxenBKZlptYVFiNmRRaFFZVGFGMWZUNUY4LTViQm5aaURMR0xfU0lF?oc=5","date":"2024-05-22","type":"pipeline","source":"Nature","summary":"One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan - Nature","headline":"One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular de","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9XUTJSQmJBeFNNNGFVSTEwZ0kzTHF0eDd2TnJPQ0hiVDJIM2FfRmJjZ3l6eGhjMnR2U1pLWThDQjNqbUtXUUp6LU1NTW5MMnFsbnQ4bkJDY3JNX1FHSlpn?oc=5","date":"2023-10-19","type":"pipeline","source":"Nature","summary":"Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis - Nature","headline":"Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQNFpweW1FeGx6b1BBdGZISVg2TVZWeFZXZHRjVTE1NjhVQk1QZ2x6THlTYnRZZDFCMEJtY3g5SHJBN0ZzNFNYQXRVYXJ6RUNwX0l6cVhtLWpwdnl0Wlg5dUh6czcxSXpJTjROR1BjSU9RZEJvX01VMjN1cWd4WUZ0R2lFWGh5eWZNT0tCNkNHZ1d2NDJtemhlVDdmMHRld2RE?oc=5","date":"2020-11-26","type":"pipeline","source":"BioSpectrum Asia","summary":"Takeda makes Nihon Pharma wholly owned subsidiary - BioSpectrum Asia","headline":"Takeda makes Nihon Pharma wholly owned subsidiary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOMHhqTTdkT0lUU2ZOMUZCeTJZbzEwOTlVaTRtNlFfWS03eWpGQ2NrNWxRbEszMGFOc1N0LTh3ZkxjVWZkdmc0Y1pFMkgzRHdiSXZWME1kYVl4NHVFa0VTa1BVYnFnNEo0QkVIZTkxbjRabU0xeVRxTTVLbmpFZ29JRFZoUDRBM1pnWEEwbzNidDhlTVVPSW02Q3pTRHRPMlh3Wm5ONXQzQ2U0Vkk1Ync2QzR3?oc=5","date":"2014-09-26","type":"pipeline","source":"msdiscovery.org","summary":"What’s the Role of Myelin Oligodendrocyte Glycoprotein in NMO? - msdiscovery.org","headline":"What’s the Role of Myelin Oligodendrocyte Glycoprotein in NMO?","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":7,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}